Giri Raghavendra, Qendro Veneta, Rani Pooja, Jepchumba Carren, Bugos Grace, Stadler Volker, Han David K
Center for Vascular Biology, Department of Cell Biology, University Connecticut School of Medicine, Farmington, CT, USA.
PEPperPrint, GmBH, Heidelberg, Germany.
Methods Mol Biol. 2019;2024:327-332. doi: 10.1007/978-1-4939-9597-4_21.
Genomics-driven immunoproteomics (GDI) is a platform that helps identify antigenic protein targets of mutations and other deoxyribonucleic acid (DNA) variations that are commonly associated with pathological states. This platform utilizes data generated from deep sequencing of exomic DNA or ribonucleic acid (RNA) as input to synthesize mutant peptides into microarrays, which then can be used to detect antigenic proteins that invoke immune response in patients. The technology has been used to detect antigenic targets of multiple sclerosis, an autoimmune disease [1], and cancer to identify mutant proteins that invoke immune response in breast cancer patients [2]. This technology has many potential applications to select genomic changes that are specifically recognized by the immune system in a rapid and efficient manner.
基因组驱动的免疫蛋白质组学（GDI）是一个有助于识别与病理状态通常相关的突变及其他脱氧核糖核酸（DNA）变异的抗原性蛋白质靶点的平台。该平台利用外显子组DNA或核糖核酸（RNA）深度测序产生的数据作为输入，将突变肽合成到微阵列中，然后可用于检测在患者体内引发免疫反应的抗原性蛋白质。该技术已被用于检测自身免疫性疾病多发性硬化症的抗原靶点[1]，以及用于癌症研究，以识别在乳腺癌患者体内引发免疫反应的突变蛋白[2]。这项技术有许多潜在应用，能够快速有效地选择被免疫系统特异性识别的基因组变化。
